Insmed Incorporated (NASDAQ:INSM) CFO Sells $1,064,160.00 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 13,302 shares of the company's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $80.00, for a total transaction of $1,064,160.00. Following the sale, the chief financial officer now owns 142,204 shares of the company's stock, valued at $11,376,320. This represents a 8.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The shares were sold at an average price of $63.72, for a total value of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The stock was sold at an average price of $65.70, for a total value of $227,979.00.

Insmed Stock Up 0.8 %

Insmed stock traded up $0.64 during mid-day trading on Monday, hitting $79.31. The company had a trading volume of 1,167,289 shares, compared to its average volume of 1,950,375. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $82.04. The company has a market capitalization of $14.19 billion, a PE ratio of -14.29 and a beta of 1.11. The stock's 50 day moving average price is $73.51 and its two-hundred day moving average price is $73.31. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Analysts Set New Price Targets

INSM has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Guggenheim lifted their target price on shares of Insmed from $95.00 to $101.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Insmed from $88.00 to $97.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Finally, Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $88.71.

Hedge Funds Weigh In On Insmed

Hedge funds have recently bought and sold shares of the company. Truist Financial Corp bought a new position in Insmed in the 2nd quarter valued at approximately $413,000. GAMMA Investing LLC boosted its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 224 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 627 shares in the last quarter. Creative Planning raised its position in Insmed by 31.2% in the 3rd quarter. Creative Planning now owns 44,914 shares of the biopharmaceutical company's stock worth $3,279,000 after buying an additional 10,668 shares during the last quarter. Finally, V Square Quantitative Management LLC bought a new position in Insmed during the 3rd quarter valued at about $30,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.